deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03347110

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis (BE ACTIVE 2)

A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Sponsor: UCB Biopharma SRL

Conditions Psoriatic Arthritis
Interventions Bimekizumab
Updated 32 times since 2017 Last updated: Nov 29, 2023 Started: Nov 22, 2017 Primary completion: Oct 29, 2020 Completion: Oct 29, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Psoriatic Arthritis, this trial is completed. The trial is conducted by UCB Biopharma SRL and has accumulated 32 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Oct 2019 · 6 months · monthly snapshot~Oct 2019 – ~Jan 2020 · 3 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Nov 2021 · 9 months · monthly snapshot~Nov 2021 – ~Apr 2022 · 5 months · monthly snapshot~Apr 2022 – ~May 2023 · 13 months · monthly snapshot~May 2023 – ~Jan 2024 · 8 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

32 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. May 2023 — Jan 2024 [monthly]

    Completed PHASE2

▶ Show 27 earlier versions

  1. Apr 2022 — May 2023 [monthly]

    Completed PHASE2

  2. Nov 2021 — Apr 2022 [monthly]

    Completed PHASE2

  3. Feb 2021 — Nov 2021 [monthly]

    Completed PHASE2

  4. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  6. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  10. Apr 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  11. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  12. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  13. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  14. Oct 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE2

  15. Apr 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

  16. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  17. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  18. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  19. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  20. Oct 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  21. Aug 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Enrolling By Invitation → Active Not Recruiting

  22. Jul 2018 — Aug 2018 [monthly]

    Enrolling By Invitation PHASE2

  23. Jun 2018 — Jul 2018 [monthly]

    Enrolling By Invitation PHASE2

    Status: Recruiting → Enrolling By Invitation

  24. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  25. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

  26. Feb 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  27. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UCB Biopharma SRL
Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bialystok, Poland , Brno, Czechia , Budapest, Hungary , Charleston, United States , Cologne, Germany , Dallas, United States , Duncansville, United States , Elblag, Poland , Erlangen, Germany , Hagerstown, United States and 20 more locations